SCHEMBL4857308

SCHEMBL4857308

C=CCC1(CCCC)CCc2cc(OC)ccc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
PRNP P04156 1/20 0.42
DGAT1 O75907 1/20 0.39
MPO P05164 1/20 0.39
CYP24A1 Q07973 2/20 0.39
METAP1 P53582 2/20 0.38
MIF P14174 3/20 0.37
CYP27A1 Q02318 1/20 0.36
ESR2 Q92731 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
CYP26A1 O43174 2/20 0.36
MALT1 Q9UDY8 1/20 0.36
LMNA P02545 1/20 0.36
CYP19A1 P11511 1/20 0.36
ESR1 P03372 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859451 0.90 METAP1 (0.40) SMN1; SMN2PRNPMPOCYP24A1METAP1
SCHEMBL629836 0.90 SMN1; SMN2 (0.53) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL4853241 0.89 SMN1; SMN2 (0.50) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL4857128 0.82 SMN1; SMN2 (0.52) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL13477035 0.82 SMN1; SMN2 (0.48) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL4860616 0.81 SMN1; SMN2 (0.51) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL6860603 0.81 METAP1 (0.47) SMN1; SMN2PRNPMPOMETAP1MIF
SCHEMBL9341449 0.80 METAP1 (0.43) SMN1; SMN2METAP1ESR2ALDH1A1LMNA
SCHEMBL629696 0.79 SMN1; SMN2 (0.58) SMN1; SMN2PRNPDGAT1MPOCYP24A1
SCHEMBL13477034 0.79 SMN1; SMN2 (0.47) SMN1; SMN2PRNPDGAT1MPOCYP24A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432284-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2008-10-07 US disclosed
US-7432284-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2008-10-07 US disclosed
US-7432284-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2008-10-07 US disclosed
US-20060041003-A1 Estrogen receptor modulators MERCK SHARP & DOHME LLC 2006-02-23 US disclosed
EP-1551820-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2005-07-13 EP disclosed
WO-2004026887-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041003-A1 Estrogen receptor modulators GPER1, ESR2, ESR1 SMN1; SMN2 1753/4885PRNP 1632/4885DGAT1 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.